BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

ADMA Biologics (ADMA)ADMA BiologicsEarnings

Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and

Related news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

RXRXRecursion2026-07-29 12:30 EST

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

RXRXRecursion2026-04-29 11:59 EST

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

ENTXEntera Bio2025-08-08 20:05 EST

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Stock data

Close
10.06 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States